Amgen (AMGN) announced that Howard Chang will join the company as Senior VP of Research, effective Dec. 16. Chang will also assume the title and responsibility of serving as Amgen’s Chief Scientific Officer, reporting to Jay Bradner, , EVP of Research and Development. Chang succeeds Ray Deshaies, former SVP of Research, whose departure was announced earlier this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs
- Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
- Amgen initiated with a Peer Perform at Wolfe Research
- Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
- Amgen call volume above normal and directionally bullish